Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can stem cell exosomes regrow hair? new trial investigates

NCT ID NCT07693244

Disease control Sponsor: Zhang Han Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This trial tests whether injections of human umbilical cord stem cell exosomes can regrow hair in men with male pattern baldness. Participants receive either the exosome treatment or a placebo injection into the scalp every four weeks for three sessions. The study measures changes in hair density and thickness over 24 weeks to see if the treatment outperforms placebo.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
human umbilical cord mesenchymal stem cell-derived exosomes
What this could lead to
If it works, this could offer a new, non-surgical treatment for male pattern baldness that stimulates hair regrowth.
What could go wrong
This is a Phase 2 trial with 120 participants, so results are still early. The treatment may not work better than placebo, and risks from scalp injections include pain, swelling, or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria Participants must meet all of the following criteria to be eligible for enrollment: 1. Male subjects aged 18 to 55 years; 2. Diagnosis of androgenetic alopecia classified as Norwood-Hamilton grade III-V; 3. Stable pattern of hair loss for at least 6 months prior to screening; 4. Willingness to refrain from using any other hair loss treatments during the study period and for 6 months after completion of treatment. Exclusion Criteria Participants meeting any of the following criteria will be excluded: 1. Other types of alopecia, including alopecia areata, cicatricial alopecia, or telogen effluvium; 2. Use of minoxidil, finasteride, spironolactone, or other hair growth-related medications within 1 year prior to screening; 3. Receipt of platelet-rich plasma (PRP), laser cap therapy, or other scalp procedures within 6 months prior to screening; 4. History of autoimmune disease, active scalp infection, coagulation disorders, or malignancy; 5. Known hypersensitivity to the investigational product or any of its components; 6. Inability to comply with study procedures, incomplete clinical data, or conditions that may interfere with efficacy evaluation; 7. Participation in another clinical trial within the study period; 8. Any condition that, in the opinion of the investigator, makes the participant unsuitable for the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Androgenetic alopecia (AGA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alopecia androgenetic alopecia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Androgenetic alopecia (AGA)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • No.28 Fuxing Road

    RECRUITING

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.